GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (FRA:MWG) » Definitions » E10

InMed Pharmaceuticals (FRA:MWG) E10 : €-691.44 (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

InMed Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was €-3.476. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-691.44 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was -3.70% per year. During the past 5 years, the average E10 Growth Rate was -4.90% per year. During the past 10 years, the average E10 Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of InMed Pharmaceuticals was 29.40% per year. The lowest was -8.40% per year. And the median was 12.30% per year.

As of today (2025-04-05), InMed Pharmaceuticals's current stock price is €1.70. InMed Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was €-691.44. InMed Pharmaceuticals's Shiller PE Ratio of today is .


InMed Pharmaceuticals E10 Historical Data

The historical data trend for InMed Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals E10 Chart

InMed Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -552.93 -587.96 -753.72 -718.42 -789.38

InMed Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -657.61 -688.84 -789.38 -591.68 -691.44

Competitive Comparison of InMed Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Shiller PE Ratio falls into.


;
;

InMed Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InMed Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-3.476/127.3637*127.3637
=-3.476

Current CPI (Dec. 2024) = 127.3637.

InMed Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 -481.023 99.789 -613.942
201506 -254.193 100.500 -322.138
201509 -109.508 100.421 -138.888
201512 -109.153 99.947 -139.095
201603 -114.149 101.054 -143.869
201606 -114.622 102.002 -143.122
201609 -111.820 101.765 -139.949
201612 -116.375 101.449 -146.103
201703 -115.685 102.634 -143.560
201706 -234.213 103.029 -289.533
201709 -111.594 103.345 -137.530
201712 -110.875 103.345 -136.644
201803 -103.619 105.004 -125.684
201806 -206.868 105.557 -249.604
201809 -218.892 105.636 -263.915
201812 -212.969 105.399 -257.351
201903 -218.731 106.979 -260.409
201906 -315.974 107.690 -373.698
201909 -245.160 107.611 -290.160
201912 -216.000 107.769 -255.273
202003 -176.475 107.927 -208.256
202006 -137.640 108.401 -161.717
202009 -131.595 108.164 -154.953
202012 -152.070 108.559 -178.411
202103 -172.200 110.298 -198.844
202106 -169.486 111.720 -193.219
202109 -104.890 112.905 -118.322
202112 -136.821 113.774 -153.164
202203 -111.502 117.646 -120.713
202206 -246.717 120.806 -260.110
202209 -82.012 120.648 -86.577
202212 -17.181 120.964 -18.090
202303 -11.208 122.702 -11.634
202306 5.169 124.203 5.301
202309 -14.280 125.230 -14.523
202312 -3.402 125.072 -3.464
202403 -3.312 126.258 -3.341
202406 -3.530 127.522 -3.526
202409 -2.442 127.285 -2.444
202412 -3.476 127.364 -3.476

Add all the adjusted EPS together and divide 10 will get our e10.


InMed Pharmaceuticals  (FRA:MWG) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


InMed Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals Headlines